Navigation Links
Astellas Adds CNS Therapy Area Leader to Global R&D Team
Date:6/4/2009

DEERFIELD, Ill., June 4 /PRNewswire/ -- Astellas Pharma Global Development ("APGD"), a subsidiary of Astellas Pharma Inc. based in Tokyo, Japan, announced today that Dr. Betsy Garofalo has been hired as the global therapy area leader for CNS. Garofalo is a pediatric neurologist and epileptologist bringing the team more than 17 years of drug development experience.

"Betsy's charge as head of the global therapy area is to provide strategic direction and leadership for the development of all Astellas CNS compounds," said Dr. Steven Ryder, president of APGD. "Betsy's deep experience in CNS disorders and past successes make her an excellent choice to help us develop new medications for the many patients with unmet medical needs."

In addition to her work at Astellas, Garofalo is an adjunct associate professor of pediatrics at the University of Michigan. In 2007, Garofalo formed the Michigan Technology and Research Institute where she provided consulting services to the pharmaceutical industry. Before that, Garofalo held numerous positions of leadership at Parke-Davis and then Pfizer Research and Development. She received her medical training and completed a pediatric residency at the Indiana University School of Medicine followed by a fellowship in neurology/pediatric neurology and a fellowship in epilepsy at the University of Michigan.

About Astellas

Astellas Pharma Global Development, located in Deerfield, Illinois, is a group company of Tokyo-based Astellas Pharma Inc. Astellas is a pharmaceutical company dedicated to improving the health of people around the world through the provision of innovative and reliable pharmaceutical products. The organization is committed to becoming a global category leader in focused areas by combining outstanding R&D and marketing capabilities. For more information about Astellas Pharma Inc., please visit the website at www.astellas.com/en/.


'/>"/>
SOURCE Astellas Pharma Global Development
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Astellas Hires New Vice President of Compliance
2. Astellas Announces New Vice President of Marketing
3. Astellas Launches Vaprisol(R) (Conivaptan Hydrochloride Injection) Premixed in 5% Dextrose for the Treatment of Hyponatremia
4. Astellas/GlaxoSmithKlines Vesicare Has Advantages Over Pfizers Detrol LA/Detrusitol XL in Reducing Episodes of Urge Urinary Incontinence
5. FDA Approves Additional Indication for Astellas MYCAMINE(R)
6. Cardiome And Astellas Announce Regulatory Update
7. Pausing Hormone Therapy Doesnt Cut Mammogram Recalls
8. Oxygen + MRI might help determine cancer therapy success, researchers find
9. QLT announces positive results from the evaluation of Visudyne(R) combination therapy
10. New Journal of Natural Medicine Launched This June, Promotes Natural Therapy
11. New Data Support Use of Simple Test to Predict Endometrial Cancer Response to Chemotherapy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2017)... ... 2017 , ... Studies show evidence that carotenoids and antioxidants derived either from ... these patients. , But how often do ophthalmologists and optometrists in Sweden recommend the ... of or with early symptoms of AMD? A study published recently in ...
(Date:6/23/2017)... ... 2017 , ... Everybody has their own personal preference when it comes to ... some people don't like it at all. FindaTopDoc took a look at what makes ... can give readers a taste of their deepest, darkest fantasies and has the ability ...
(Date:6/23/2017)... ... June 23, 2017 , ... Georgia State University will ... 20. , The two-day conference is focused on advancing scientific knowledge about the ... lives and eliminating racial breast cancer-related disparities. The conference theme is “Illuminating Actionable ...
(Date:6/23/2017)... ... June 23, 2017 , ... Ross Insurance ... With the Federal Emergency Management Agency’s (FEMA) recent update of flood zones, more ... 2012, the Biggert-Waters Act was enacted to reflect the actual risk in flood ...
(Date:6/23/2017)... ... June 23, 2017 , ... ... planning services to communities in the greater Chicago metropolitan area, is embarking on ... to underprivileged youth in Chicago. , Founded in 1897, Hephzibah Children’s Association is ...
Breaking Medicine News(10 mins):
(Date:6/8/2017)... 2017  Less than a month ago, amateur hackers ... companies, including hospital networks, in over 150 countries. ... the largest online extortion attempts ever recorded. With the ... is imperative that providers understand where the risks lie, ... — and many other very real cyber threats.  ...
(Date:6/7/2017)... 7, 2017  Novavax, Inc., (Nasdaq: NVAX ) ... 2 trials of its RSV F protein recombinant nanoparticle vaccine ... have been published in the journal Vaccine ... in prior scientific conferences). The Company previously announced top ... is developing the RSV F Vaccine with the goal of ...
(Date:6/3/2017)... INDIANAPOLIS , June 3, 2017  Eli ... today announced that results from the Phase 3 ... kinase (CDK)4 & 6 inhibitor, in combination with ... treatment with fulvestrant alone in women with hormone-receptor-positive ... advanced breast cancer who have relapsed or progressed ...
Breaking Medicine Technology: